生活方式与药物方法预防代谢功能障碍相关脂肪性肝病相关肝细胞癌
综述阐述MASLD相关肝细胞癌的发病机制,并讨论新兴的药物与生活方式干预。健康饮食模式和增加体力活动与较低HCC风险相关;二甲双胍、PPAR激活剂、SGLT2抑制剂、DPP-4抑制剂、GLP-1受体激动剂、阿司匹林和他汀均显示降低HCC风险的希望,但指南目前不推荐仅用于化学预防。
要点
- 健康饮食模式(多蔬果、全谷物、鱼禽、酸奶、橄榄油,少红肉加工肉和糖)与较低HCC风险相关。
- 增加体力活动与较低HCC风险相关。
- 多种降糖药、阿司匹林和他汀显示降低HCC风险的希望,但指南不推荐仅用于化学预防。
核心结论
- 健康生活方式行为和选择适当的药物方法可能降低MASLD患者HCC的发生风险。
- 尽管二甲双胍、PPAR激活剂、SGLT2抑制剂、DPP-4抑制剂、GLP-1受体激动剂、阿司匹林和他汀均显示降低HCC风险的希望,但指南目前不推荐仅用于化学预防,因缺乏定义其风险获益比的数据。
研究设计与样本
- 综述,描述MASLD患者HCC的发病机制并讨论新兴的药物与生活方式干预。
主要发现
- 健康饮食模式(如高摄入蔬菜、全谷物、鱼禽、酸奶和橄榄油,低摄入红肉、加工肉类和膳食糖)与较低HCC风险相关。
- 增加体力活动与较低HCC风险相关。
- 二甲双胍、PPAR激活剂、SGLT2抑制剂、DPP-4抑制剂、GLP-1受体激动剂、阿司匹林和他汀均显示降低HCC风险的希望。
关键数值与推荐
- 指南目前不推荐将二甲双胍、PPAR激活剂、SGLT2抑制剂、DPP-4抑制剂、GLP-1受体激动剂、阿司匹林或他汀仅用于HCC化学预防,因缺乏定义其风险获益比的数据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is a major concern for public health. Fatty liver disease, related to alcohol misuse or metabolic syndrome, has become the leading cause of chronic liver disease and HCC. The strong association between type 2 diabetes mellitus and HCC can be partly attributed to the development of metabolic dysfunction-associated steatotic liver disease (MASLD). There is a strong interest in strategies that may mitigate HCC risk and reduce HCC incidence in this growing population of at-risk individuals. In this review, we describe the pathogenesis of HCC in patients with MASLD and discuss potential emerging pharmacological and lifestyle interventions for MASLD-related HCC. HCC risk has been observed to be lower with healthy lifestyle behaviors, such as healthy dietary patterns (eg, high consumption of vegetables, whole grains, fish and poultry, yogurt, and olive oil, and low consumption of red and processed meats and dietary sugar) and increased physical activity. Selecting an appropriate pharmacologic approach for individuals with MASLD may also decrease the occurrence of HCC. Metformin, PPAR activators, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, aspirin, and statins have all shown promise to reduce the risk of HCC, although guidelines do not recommend their use for the sole purpose of chemoprevention at this time, given a dearth of data defining their risk-benefit ratio.
引用
- Cheraghpour M, Hatami B, Singal AG, et al. Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2025. PMID: 39800201. doi:10.1016/j.cgh.2024.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。